Survodutide
BI 456906
- Molecular form
- Modified peptide analog
Modified peptide analog
Open the sources to check how the studies were done and what they can support.
A dual GLP-1 and glucagon receptor agonist with randomized human obesity research.
- Family
- Dual metabolic receptor agonist
- Research target
- GLP-1 and glucagon receptors
- Molecular form
- Modified peptide analog
What to know about the research
The published phase 2 study is a dated evidence anchor. Review later trial records and tolerability alongside changes in body weight.
Check the exact compound
This receptor pair differs from tirzepatide’s GIP/GLP-1 profile and retatrutide’s triple profile.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries